Replies to post #245384 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

"I don't think the pipeline is valued at all. I think it is HOPE in the pipeline that is keeping the stock afloat."

I actually think this is dead on accurate. Elite has stated they have 17 abuse deterrent product candidates including a once-daily ADT opioid technology scaled up to Phase 3's doorstep. ELI-201 has had multiple successful BE trials. SequestOx is a couple of bridging studies and a Category 1 abuse study away from resubmission. Multiple (Percocet, Norco) ANDAs filed with 700 million dollar markets. If the actual pipeline was valued at all, we'd be way higher than 13 cents.

[Couch]

Now we have something. So in essence Elite's ADT hasn't been put into the PPS equation at all at this point. Nasrat helps Alpharma launch Embeda and he says Elite has better technology than what Pfizer bought. He and Doug Plassche would know this. So regarding SequestOx - positive efficacy data, positive HAL data and waiting on BE data for the TMax issue.

Thanks I think we finally agree on something. And that "gamble" - I continue to take that gamble. The generic pipeline alone is worth more than the current PPS.

Tell me again how many generic AD OxyContin products on the market???